Clinical Trials Directory

Trials / Completed

CompletedNCT04032977

Safety and Effectiveness of PN40082 for Lip Augmentation

A Multicenter, Double-blind, Randomized, Controlled Study of the Safety and Effectiveness of PN40082 for Lip Augmentation

Status
Completed
Phase
Study type
Interventional
Enrollment
158 (actual)
Sponsor
Prollenium Medical Technologies Inc. · Industry
Sex
All
Age
21 Years
Healthy volunteers
Accepted

Summary

To compare the safety and efficacy profile of PN40082 versus Restylane Silk Injectable Gel with 0.3% lidocaine (Restylane Silk) for lip augmentation in approximately 158 subjects.

Detailed description

The objective of the study is to compare the safety and efficacy profile of PN40082 versus Restylane Silk Injectable Gel with 0.3% lidocaine (Restylane Silk) for lip augmentation. Approximately 158 subjects will be randomized at approximately 7 sites in this is a double-blind, randomized, controlled, multicenter clinical study of subjects seeking lip augmentation. Subjects meeting inclusion/exclusion criteria will be randomized 1:1 to treatment with either PN40082 or Restylane Silk. The Evaluating Investigator will be blinded to the treatment. Injections of the study device will be performed by an unblinded Treating Investigator. At each visit, the blinded Evaluating Investigator evaluations and subject evaluations of the treated areas will be performed and recorded. Visits and telephone contacts will occur at: Visit 1 / Week 0 (Day 1) - baseline and treatment * Day 3 (±2 days) - Safety follow-up telephone call * Day 14 (±2 days) - Safety follow-up telephone call Visit 2 / Day 28 (±2 days) / Month 1 - interim visit (touch-up if necessary) * Day 33 (±2 days) - Safety follow-up telephone call (for subjects with touch-up treatment * Day 44 (±2 days) - Safety follow-up telephone call (for subjects with touch-up treatment) Visit 3 / Day 56 (±4 days) / Month 2 - interim visit Visit 4 / Day 84 (±4 days) / Month 3 - interim visit * Day 112 (±4 days) / Month 4 - Safety follow-up telephone call * Day 140 (±4 days) / Month 5 - Safety follow-up telephone call Visit 5 / Day 168 (±7 days) / Month 6 - End of Study (EOS) Visit. All subjects will undergo the consent procedure for the open label retreatment protocol. Evaluations include: Lip Fullness Grading Scale (LFGS) (Overall lip fullness considering both lips together, fullness of the upper lip and fullness of the lower lip) Perioral lines at rest severity scale (POL) (Overall perioral lines at rest severity considering both lips together, perioral lines at rest severity of the upper lip and perioral lines at rest severity of the lower lip) Patient Global Aesthetic Improvement (pGAI) Investigator Global Aesthetic Improvement (iGAI) Safety will be assessed by monitoring adverse events (AEs) at all study visits Other Safety Evaluations include: Lip Function Lip Sensation Other evaluations include: Investigator Ease of Use Assessment Swelling Assessment Subject Satisfaction with Lips Assessment Subjects participation will be approximately 6 months and the study is estimated to last 20 months from first subject first visit to last subject last visit.

Conditions

Interventions

TypeNameDescription
DEVICEPN40082To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
DEVICERestylane SilkTo provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips

Timeline

Start date
2018-07-13
Primary completion
2019-05-03
Completion
2019-05-03
First posted
2019-07-25
Last updated
2021-07-12
Results posted
2021-07-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04032977. Inclusion in this directory is not an endorsement.